Autres langues GeNeuro SA

Actions

GNRO

CH0308403085

Marché Fermé - Euronext Paris Autres places de cotation 17:35:04 10/06/2024			Varia. 5j.	Varia. 1 janv.
1,95 ^EUR	-5,34 %		-1,27 %	+78,90 %

16/05	Le plafond boursier a sauté
16/05	En Direct des Marchés : Vallourec, Ubisoft, Cisco, Euronext, Netflix, Siemens, Chubb...

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Availability of documents and information for the annual shareholders’ meeting of June 12, 2024	29/05
GeNeuro Announces Last Patient Last Visit in its Post-COVID Trial and Confirms Top-Line Results by End of June 2024	16/05
GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024	16/05
GeNeuro Publishes its 2024 Universal Registration Document	02/05
GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update	30/04
GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting	20/03
Geneuro SA Announces Appointments of Board of Directors	20/03
GeNeuro SA Reports Earnings Results for the Full Year Ended December 31, 2023	05/02
GeNeuro : le titre chute après un placement privé	02/02
GeNeuro Raises EUR5 Million from Share Issue	02/02
GeNeuro : nomination d'une nouvelle directrice médicale	08/01
Geneuro Sa Announces Executive Changes	05/01
GeNeuro : Citigroup Global Markets Ltd franchit les 5%	05/01
GeNeuro - Independent Data Monitoring Committee recommends continuing the trial evaluating temelimab in Long COVID without any modifications	12/12
GeNeuro : avis positif pour la poursuite d'un essai	11/12
GeNeuro's Mid-stage Study for Post-COVID Symptoms Therapy Gets Medical Committee's Nod	11/12
Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications	11/12
GeNeuro Finalizes Patient Enrollment in Early-stage Trial of Long-COVID Treatment	28/11
GeNeuro : fin du recrutement de l'essai dans le Covid long	28/11
GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024	28/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues GeNeuro SA

Actions

GNRO

CH0308403085

Autres langues

Filtres